Search clinical trials for: Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle Vaccine

Total 68 results

Kenya Medical Research Institute
University of Washington

Not yet recruiting

Effectiveness and B-memory Cell Response to QHPV Vaccine 9-years Post-vaccination Among HIV-infected Boys and Girls

HPV-Related Carcinoma
National Cancer Institute (NCI)

Active, not recruiting

Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial

Human Papillomavirus-Related Cervical Carcinoma

Costa Rica
Kenya Medical Research Institute
Merck Sharp & Dohme LLC; University of Washington

Completed

Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys

HPV Infection | HPV Vaccine | HIV-1-infection

Kenya
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

HIV Infections | Sexually Transmitted Diseases

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)

Condyloma Acuminata | Anogenital Human Papilloma Virus Infection
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)

Papillomavirus Infections
Merck Sharp & Dohme LLC

Suspended

Tolerability and Immunogenicity of Gardasil in Females Between 16 and 23 Years of Age in India (V501-034)

HPV Infections
GlaxoSmithKline

Completed

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

Cervical Cancer | Precancerous Condition

Costa Rica
Medstar Health Research Institute
Merck Sharp & Dohme LLC

Completed

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

Cervical Cancer | Warts | Hpv

United States
Merck Sharp & Dohme LLC

Completed

An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035)

HPV Infections
PATH
National Institute of Hygiene and Epidemiology, Vietnam

Completed

Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil

Dose Schedule Study

Vietnam
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

Prevention | Papillomavirus Infection | Healthy Adult Female Participants | Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
Prof. Jan Prins

Completed

HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN) (VACCAIN-P)

HIV | AIN

Netherlands
Merck Sharp & Dohme LLC

Completed

An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)

Papillomavirus Infections
Merck Sharp & Dohme LLC

Completed

GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)

Papillomavirus Infections
AIDS Malignancy Consortium
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; University of Arkansas and other collaborators

Completed

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Precancerous Condition | Anal Cancer | Penile Cancer | Nonneoplastic Condition

United States, Puerto Rico
Merck Sharp & Dohme LLC

Completed

Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)

Neoplasms, Glandular and Epithelial | Whooping Cough | Tetanus | Diphtheria | Poliomyelitis
Merck Sharp & Dohme LLC

Completed

V501 Efficacy Study in Women Aged 18 to 26 (V501-027)

HPV Infections
Shanghai Bovax Biotechnology Co., Ltd.

Terminated

A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | CIN1 | CIN2 | CIN3 | Genital Wart | AIS | Vain I | Vain III | Vin I | Vin II | Vin III | VAIN - Vaginal Intraepithelial Neoplasia 2

China
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females

Infections, Papillomavirus | Papillomavirus Vaccines

Thailand, Estonia, India, Brazil
Chulalongkorn University

Unknown

The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in Chronic Kidney Disease (CKD) Patients

Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease, Stage V

Thailand
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Human Papillomavirus Vaccine Therapy in Treating Men With HIV-1 Infection

Infection | Precancerous Condition

United States
National Cancer Institute (NCI)

Active, not recruiting

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (PRISMA)

Cervical Carcinoma | Human Papillomavirus Infection

Costa Rica
University Hospital, Ghent

Completed

Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®) (HPVXneutra001)

Infection With Human Papillomavirus

Belgium
GlaxoSmithKline

Completed

Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.

Infections, Papillomavirus

Belgium, United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts
National Cancer Institute (NCI)
Bill and Melinda Gates Foundation

Enrolling by invitation

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (ESCUDDO)

Human Papillomavirus Infection | Human Papillomavirus-Related Cervical Carcinoma

Costa Rica
Merck Sharp & Dohme LLC

Completed

Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)

HPV Infections
University of Alabama at Birmingham
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors

Cancer Survivor | Prevention of Human Papillomavirus Infection

United States
Merck Sharp & Dohme LLC

Completed

V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)

HPV Infections
Merck Sharp & Dohme LLC

Completed

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Human Papillomavirus Infection
GlaxoSmithKline

Completed

Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects

Infections, Papillomavirus

Germany, Spain, France
GlaxoSmithKline

Completed

A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females

Infections, Papillomavirus

China
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Malaysia
University of Milan

Unknown

Long Term Immunogenicity of Quadrivalent Human Papillomavirus Vaccine (Gardasil®)in HIV-infected Adolescents and Young Adults

HIV | HPV

Italy
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Vaccine Therapy in Preventing HPV in HIV-Positive Women in India

Cervical Cancer | Precancerous Condition | Nonneoplastic Condition

India
Merck Sharp & Dohme LLC

Active, not recruiting

Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil) (V501-015) (FUTURE II)

Cervical Cancer | Genital Warts
University of North Carolina, Chapel Hill

Completed

Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women

HIV Infection

United States, Puerto Rico
National Institute for Control of Vaccine and Biologicals

Unknown

Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule (HPV-022 PRI)

Human Papillomavirus (HPV) Vaccine

Vietnam
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)

Prevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in Situ

China
Merck Sharp & Dohme LLC

Completed

Study of an Investigational Vaccine in Pre-Adolescents and Adolescents (Gardasil)(V501-016)

Cervical Cancer | Genital Warts
Merck Sharp & Dohme LLC

Completed

An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

Condylomata Acuminata
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age

Infections, Papillomavirus

Japan
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Jiangsu Province Centers... and other collaborators

Completed

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Human Papilloma Virus Infection

China
Beijing Health Guard Biotechnology, Inc

Active, not recruiting

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Human Papillomavirus Infection

China
GlaxoSmithKline

Completed

Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years

Infections, Papillomavirus

Malaysia
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts

Austria, Belgium, Finland, Germany, Italy, Spain
Beijing Health Guard Biotechnology, Inc
University of Muhammadiyah Malang Hospital; Dr. M Djamil Hospital, Padang

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Human Papillomavirus Infection

Indonesia
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Yunnan Center for Disease... and other collaborators

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Human Papillomavirus Infection

China
Merck Sharp & Dohme LLC

Completed

Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED)

Cervical Cancer | Genital Warts

3

Subscribe